BMY - Week In Review: Hansoh Signs $456 Million Deal For siRNA Products

• Hansoh Pharma of Shanghai announced a $456 million agreement to develop siRNA products in Greater China from South Korea's OliX Pharma.
• The $1.4 billion landmark deal between Beijing's BeiGene and Celgene (now Bristol-Myers) is falling apart. The companies are arguing over BeiGene's China distribution rights for Abraxane, a nanoparticle albumin–bound form of paclitaxel, used to treat several forms of cancer.
• Suzhou Kintor Pharma was approved to start a China Phase I trial of its ALK-1 antibody in combination with Bristol-Myers Squibb's PD-1, nivolumab (Opdivo), in patients with advanced hepatocellular carcinoma.

For further details see: